Skip to content

Study · Non-randomized trial · n = 42 · 2026

6 results

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.

Oldenburg LIK, Haugaard SP, Karlsson T, Kegel-Hübner V, Parwez M, Wiingaard C, Flint A

Diabetes, obesity & metabolism13 Jul 2026Cited by 1 (Europe PMC)

PMID42443140 (opens in a new tab)PMCIDPMC13538736 (opens in a new tab)DOI10.1111/dom.71096 (opens in a new tab)PepBankPUB-42443140
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In adults, zenagamtide AUC ranged from 520-715 h × nmol/L across renal impairment groups versus 543 with normal renal function.

    In plain wordsIn adults, zenagamtide exposure varied across renal impairment groups compared with normal renal function.

    Peptide
    Amycretin
    Outcome
    MixedAUC across renal impairment groups
    Study

    n = 42

    Comparator
    normal renal function
    Analysis
    Primary
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3 mg · subcutaneous · single doseAs given in this study (human).

    Measurements

    AUC0-inf
    520 to 715 h × nmol/L
    geometric mean, renal impairment groups
    AUC0-inf
    543 h × nmol/L
    geometric mean, normal renal function group

    Source sentences

    Summary
    The range (geometric mean) of zenagamtide AUC0-∞ and C max across renal impairment groups were 520-715 h × nmol/L and 2.8-3.5 nmol versus 543 h × nmol/L and 3.2 nmol/L for the normal renal function group, respectively.
    1 context sentence
    Summary · context
    Participants received a single subcutaneous dose of zenagamtide 0.3 mg, followed by a 4-week follow-up period.
  2. 02HumanNon-randomized trialPharmacokinetics

    In adults, maximum zenagamtide concentrations varied across renal impairment groups compared with normal renal function.

    In plain wordsIn adults, peak zenagamtide concentrations varied across renal impairment groups compared with normal renal function.

    Peptide
    Amycretin
    Outcome
    MixedMaximum plasma concentration
    Study

    n = 42

    Comparator
    normal renal function
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3 mg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Cmax
    2.8 to 3.5 nmol
    geometric mean, renal impairment groups
    Cmax
    3.2 nmol/L
    geometric mean, normal renal function group

    Source sentences

    Summary
    The range (geometric mean) of zenagamtide AUC0-∞ and C max across renal impairment groups were 520-715 h × nmol/L and 2.8-3.5 nmol versus 543 h × nmol/L and 3.2 nmol/L for the normal renal function group, respectively.
    1 context sentence
    Summary · context
    Participants received a single subcutaneous dose of zenagamtide 0.3 mg, followed by a 4-week follow-up period.
  3. 03HumanNon-randomized trialSafety outcome

    Among zenagamtide recipients, 30 participants reported treatment-emergent adverse events, representing 71.4% of participants.

    In plain wordsAmong zenagamtide recipients, 71.4% reported adverse events after treatment.

    Peptide
    Amycretin
    Outcome
    Not applicableTreatment-emergent adverse events
    Study

    n = 42

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.3 mg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Participants with treatment-emergent adverse events
    30 participants
    all participants
    Proportion with treatment-emergent adverse events
    71.4%
    all participants

    Source sentences

    Summary
    Overall, TEAEs were reported in 30 (71.4%) participants.
    1 context sentence
    Summary · context
    Participants received a single subcutaneous dose of zenagamtide 0.3 mg, followed by a 4-week follow-up period.
  4. 04HumanNon-randomized trialSafety outcome

    In adults receiving zenagamtide, treatment-emergent adverse events were non-serious.

    In plain wordsIn adults receiving zenagamtide, reported adverse events were not serious.

    Peptide
    Amycretin
    Outcome
    Not applicableSerious adverse events
    Study

    n = 42

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.3 mg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    TEAEs were non-serious, none were severe and the majority were mild and most frequently gastrointestinal in nature.
    1 context sentence
    Summary · context
    Participants received a single subcutaneous dose of zenagamtide 0.3 mg, followed by a 4-week follow-up period.
  5. 05HumanNon-randomized trialSafety outcome

    In adults receiving zenagamtide, no treatment-emergent adverse events were severe and most were mild.

    In plain wordsIn adults receiving zenagamtide, no reported adverse events were severe and most were mild.

    Peptide
    Amycretin
    Outcome
    Not applicableAdverse event severity
    Study

    n = 42

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.3 mg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    TEAEs were non-serious, none were severe and the majority were mild and most frequently gastrointestinal in nature.
    1 context sentence
    Summary · context
    Participants received a single subcutaneous dose of zenagamtide 0.3 mg, followed by a 4-week follow-up period.
  6. 06HumanNon-randomized trialSafety outcome

    In adults receiving zenagamtide, treatment-emergent adverse events were most frequently gastrointestinal.

    In plain wordsIn adults receiving zenagamtide, digestive problems were the most frequent adverse events.

    Peptide
    Amycretin
    Outcome
    Not applicableGastrointestinal adverse events
    Study

    n = 42

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.3 mg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    TEAEs were non-serious, none were severe and the majority were mild and most frequently gastrointestinal in nature.
    1 context sentence
    Summary · context
    Participants received a single subcutaneous dose of zenagamtide 0.3 mg, followed by a 4-week follow-up period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT06559527

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Novo Nordisk A/Sn = 4220 Aug 2024 to 5 Mar 2025

Diabetes Mellitus, Type 2 · Obesity · Overweight

Trial pageClinicalTrials.govUpdated 30 Mar 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.